BIOMX INC. news, videos and press releases
For more news please use our advanced search feature.
BIOMX INC. - More news...
BIOMX INC. - More news...
- BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
- BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
- BiomX Announces the Appointment of Susan Blum to its Board of Directors
- BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
- BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
- BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
- BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
- BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
- BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
- BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
- BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
- BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
- BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
- BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference
- BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
- BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
- NYSE American Initiates Delisting Proceedings for BiomX Warrants
- BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)
- BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
- BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
- BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023
- BiomX Announces Second Closing of $7.5 Million Private Placement
- BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
- BiomX Announces $7.5 Million Private Placement
- BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
